Feng Ye

机构：Sichuan University, Foundation Center, First Affiliated Hospital of Xiamen University, West China Hospital of Sichuan University, Beijing Anzhen Hospital, PharmacoGenetics (China), Shanghai Sunshine Rehabilitation Center, First Affiliated Hospital Zhejiang University, Jiangxi Agricultural University, Zhejiang University, The University of Texas Southwestern Medical Center · ORCID：0000-0002-4983-8520

发表论文 218 篇 · 总被引 5697 次 · h-index 39

代表论文

• Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers (2024 · Drug Resistance Updates · 被引 115)
• First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study (2024 · Nature Medicine · 被引 56)
• Super enhancers targeting ZBTB16 in osteogenesis protect against osteoporosis (2023 · Bone Research · 被引 26)
• Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial (2024 · European Journal of Cancer · 被引 21)
• Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer (2024 · Thoracic Cancer · 被引 19)
• Multi-omics uncovers immune-modulatory molecules in plasma contributing to resistance exercise-ameliorated locomotor disability after incomplete spinal cord injury (2025 · Genome Medicine · 被引 11)